Table 1 Survival analyses for TP53 somatic mutations defined by transcriptional activity and stratified by hypermutation status.

From: Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival

Mutation group

Hypermutation status

Cases (n)

CRC-specific deaths (n)

HR

95% CIa

P valuea

>5% residual activity or no mutation

Combined

1083

169

1.00

(Ref)

–

NHM

806

150

1.00

(Ref)

–

HM

277

19

1.00

(Ref)

–

>0% to <5% residual activity

Combined

102

23

1.38

0.89–2.13

0.15

NHM

85

20

1.29

0.81–2.05

0.29

HM

17

3

2.38

0.68–8.38

0.18

0% residual activity

Combined

484

121

1.53

1.21–1.94

3.8 × 10−4

NHM

440

117

1.52

1.19–1.94

7.4 × 10−4

HM

44

4

1.29

0.42–3.90

0.66

  1. CRC colorectal cancer, NHM non-hypermutated, HM hypermutated, HR hazard ratio, CI confidence interval.
  2. aCox proportional hazard regression models adjust for age at diagnosis, sex, mutation burden, and study. TP53 non-silent mutations are based on transcript NM000546.
Back to article page